LeMaitre Vascular, Inc. (LMAT) — ESG & Values Scores

Environment story

LeMaitre Vascular discloses minimal environmental data. No Scope 1, 2, or 3 emissions are reported in the 10-K. The company acknowledges regulatory compliance with environmental laws but does not articulate a net-zero commitment or decarbonization roadmap. The 10-K notes reliance on chemicals and substances for manufacturing and sterilization without disclosing substitution plans or intensity metrics. Product material sourcing (bovine, ovine tissue) raises regulatory scrutiny regarding supply-chain sustainability, though no material environmental controversies, fines, or toxic-waste issues are documented. The lack of disclosed targets, emissions baselines, and renewable-energy commitments places the company in a mediocre posture; absence of greenwashing claims prevents further deduction.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Environmental Compliance Framework

Company states compliance with federal, state, and local environmental laws governing hazardous substance use, storage, air emission, and effluent discharge. No non-compliance has been required to date according to 10-K disclosure.
Regulatory Oversight of Animal-Derived Materials

Products containing bovine (AlboGraft, Artegraft, XenoSure, CardioCel, VascuCel) and ovine (Omniflow II) materials are subject to increasing regulatory scrutiny regarding BSE transmission risk and source-country certification requirements (e.g., Australia, New Zealand sourcing).

Social story

LeMaitre reports 655 employees (646 full-time) as of December 31, 2025, with an 8.8% voluntary resignation rate in 2025. The company uses third-party wage benchmarks and enhanced 401(k) matching (3% to 4%) and reduced vesting (6 to 3 years) in 2025, signaling competitive compensation practices. No disclosed CEO-to-median-worker pay ratio is provided; no union-suppression activities or major strikes are documented. Leadership and board diversity percentages are not explicitly reported in the 10-K, limiting granular assessment. Supply-chain human-rights audits are not disclosed; tissue procurement from donation organizations introduces governance complexity but no documented labor-exploitation hazards are cited. No NLRB complaints, litigation, or documented workplace safety violations are mentioned. The company maintains employee development and competitive benefits, though diversity metrics remain opaque.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Competitive Compensation & Benefits Program

Uses third-party wage benchmarks. In 2025, increased 401(k) employer match from 3% to 4% and reduced vesting period from 6 years to 3 years. Annual review of benefits competitiveness with external consultants.

Enhanced retirement savings accessibility and employee retention incentive.
Monthly Workforce Monitoring

On a monthly basis, company reviews hiring needs, new hires, and voluntary resignation rates to manage human capital.

Governance story

LeMaitre Vascular's governance structure exhibits moderate transparency. The company discloses board independence as a governance priority but does not explicitly state the independence percentage in the 10-K excerpt provided. No dual-class share structure is mentioned, suggesting single-class voting. The company acknowledges reliance on long-tenured executive leadership (CEO, President, Senior Vice President of Operations) with significant institutional knowledge but does not disclose key-person life insurance, presenting potential continuity risk. Lobbying expenditures are not quantified in the 10-K. The company has experienced recent FDA regulatory enforcement (April 2025 warning letter at North Brunswick facility with eight observations; April 2025 voluntary product notification for catheter seal defects) and a January 2026 cybersecurity incident requiring third-party forensic support. Board committees (Audit, Compensation, Nominating and Corporate Governance) are established with published charters. No antitrust proceedings, consumer-fraud SEC consent decrees, or material financial penalties are documented. The company maintains MDSAP certification and international regulatory compliance across multiple jurisdictions.

Criticisms on file

FDA Warning Letter & Inspection Findings (April 2025)
Source: LMAT 10-K (Item 1A Risk Factors & Business Description); August 2025 FDA warning letter issued; company responded to all cited observations; FDA indicated follow-up reinspection to confirm corrective actions.
Voluntary Product Notification for Packaging Defect (April 2025)
Source: LMAT 10-K; company voluntarily notified regulatory bodies of inadequate seal on TufTex Over-the-Wire, Pruitt Occlusion, and Pruitt Irrigation catheters; customers offered product replacement.
Cybersecurity Incident (January 2026)
Source: LMAT 10-K; company experienced cybersecurity incident and activated incident response plan; engaged third-party external advisors; critical systems restored; investigation into potentially impacted data remains ongoing; company believes incident has not had material impact on financial condition or operations as of 10-K date.

Disclosed initiatives

Board Committee Structure & Governance Guidelines

Company maintains Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee with published charters. Corporate Governance Guidelines and Code of Business Conduct and Ethics available on website.

Structured governance and transparent committee oversight.
Regulatory Compliance & Quality Management

Company maintains MDSAP certification across U.S., Japan, Australia, Canada, and Brazil. Implements FDA QMSR and current Good Tissue Practices. Subject to regular FDA and international regulatory inspections.

Multi-jurisdictional regulatory compliance and quality assurance framework.
Cybersecurity Incident Response

January 2026 cybersecurity incident triggered activation of incident response plan; engaged third-party external advisors for containment, mitigation, and investigation. Critical systems securely restored with minimal disruption to manufacturing and distribution.

Responsive incident management; no material financial or operational impact reported as of 10-K filing date.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of LeMaitre Vascular, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open LeMaitre Vascular, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)